Current recommendations for Helicobacter pylori therapies in a world of evolving resistance

References

• Bazzoli F, Zagari R, Fossi S, et al. Efficacy and tolerability of a short-term low-dose triple therapy for eradication of Helicobacter pylori.. Am J Gastroenterol 1993; 104:40A
   Google Scholar
• Lamouliatte HC, Cayla R, Megraud F, Zerbib F, Stablo M, Bouchard S, et al. Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection. Acta Gastroenterol Belg 1993; 56:A140
   Google Scholar
• Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O’Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1:138 - 44; http://dx.doi.org/10.1111/j.1523-5378.1996.tb00027.x; PMID: 9398894
   PubMedGoogle Scholar
• Lind T, Mégraud F, Unge P, Bayerdörffer E, O’morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116:248 - 53; http://dx.doi.org/10.1016/S0016-5085(99)70119-8; PMID: 9922303
   PubMed Web of Science ®Google Scholar
• European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8 - 13; http://dx.doi.org/10.1136/gut.41.1.8; PMID: 9274464
   PubMed Web of Science ®Google Scholar
• Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13:1 - 12; http://dx.doi.org/10.1111/j.1440-1746.1998.tb00537.x; PMID: 9737564
   PubMed Web of Science ®Google Scholar
• Coelho LG, León-Barúa R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95:2688 - 91; http://dx.doi.org/10.1016/S0002-9270(00)01967-5; PMID: 11051336
   PubMed Web of Science ®Google Scholar
• Borody TJ, George LL, Brandl S, Andrews P, Lenne J, Moore-Jones D, Devine M, Walton M. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol 1992; 27:281 - 4; http://dx.doi.org/10.3109/00365529209000075; PMID: 1589705
   PubMed Web of Science ®Google Scholar
• Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori.. Gastroenterology 1996; 111:886 - 900; http://dx.doi.org/10.1016/S0016-5085(96)70056-2; PMID: 8831583
   PubMed Web of Science ®Google Scholar
• Sachs G, Meyer-Rosberg K, Hong C, Melchers K, Scott D.. Biologie de Helicobacter pylori dans l'estomac. La lettre de l'Infectiologue 1997; 12:16 - 20
   Google Scholar
• Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idström JP, Cederberg C, Spiller RC. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111:358 - 67; http://dx.doi.org/10.1053/gast.1996.v111.pm8690200; PMID: 8690200
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Mégraud F. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori.. J Antimicrob Chemother 2002; 50:865 - 72; http://dx.doi.org/10.1093/jac/dkf219; PMID: 12461005
   PubMed Web of Science ®Google Scholar
• Nakamura M, Spiller RC, Barrett DA, Wibawa JI, Kumagai N, Tsuchimoto K, Tanaka T. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 2003; 8:294 - 9; http://dx.doi.org/10.1046/j.1523-5378.2003.00156.x; PMID: 12950601
   PubMed Web of Science ®Google Scholar
• Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20:280 - 322; http://dx.doi.org/10.1128/CMR.00033-06; PMID: 17428887
   PubMed Web of Science ®Google Scholar
• Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.. Antimicrob Agents Chemother 1996; 40:477 - 80; PMID: 8834903
   PubMed Web of Science ®Google Scholar
• Occhialini A, Urdaci M, Doucet-Populaire F, Bébéar CM, Lamouliatte H, Mégraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41:2724 - 8; PMID: 9420046
   PubMed Web of Science ®Google Scholar
• Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374 - 84; http://dx.doi.org/10.1136/gut.2003.022111; PMID: 15306603
   PubMed Web of Science ®Google Scholar
• Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.. Antimicrob Agents Chemother 1995; 39:107 - 11; http://dx.doi.org/10.1128/AAC.39.1.107; PMID: 7695290
   PubMed Web of Science ®Google Scholar
• Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.. Antimicrob Agents Chemother 2003; 47:3942 - 4; http://dx.doi.org/10.1128/AAC.47.12.3942-3944.2003; PMID: 14638505
   PubMed Web of Science ®Google Scholar
• Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14:1339 - 43; http://dx.doi.org/10.1046/j.1365-2036.2000.00846.x; PMID: 11012480
   PubMed Web of Science ®Google Scholar
• Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39:1001 - 5; http://dx.doi.org/10.1016/j.dld.2007.06.016; PMID: 17889627
   PubMedGoogle Scholar
• Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori.. Antimicrob Agents Chemother 1999; 43:1497 - 9; PMID: 10348780
   PubMed Web of Science ®Google Scholar
• Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H, Saito Y, Kobayashi I, Hibi T. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.. Digestion 2009; 79:1 - 4; http://dx.doi.org/10.1159/000191204; PMID: 19142036
   PubMed Web of Science ®Google Scholar
• Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002; 184:2131 - 40; http://dx.doi.org/10.1128/JB.184.8.2131-2140.2002; PMID: 11914344
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18:206 - 14; http://dx.doi.org/10.1111/hel.12031; PMID: 23241101
   PubMed Web of Science ®Google Scholar
• Ribeiro ML, Gerrits MM, Benvengo YH, Berning M, Godoy AP, Kuipers EJ, Mendonça S, van Vliet AH, Pedrazzoli J Jr., Kusters JG. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol 2004; 40:57 - 61; http://dx.doi.org/10.1016/S0928-8244(03)00277-3; PMID: 14734187
   PubMed Web of Science ®Google Scholar
• Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012; 27:493 - 7; http://dx.doi.org/10.1111/j.1440-1746.2011.06874.x; PMID: 21793912
   PubMed Web of Science ®Google Scholar
• Suzuki RB, Almeida CM, Sperança MA. Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2012; 12:49; http://dx.doi.org/10.1186/1471-230X-12-49; PMID: 22594560
   PubMed Web of Science ®Google Scholar
• Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori.. Antimicrob Agents Chemother 2002; 46:2229 - 33; http://dx.doi.org/10.1128/AAC.46.7.2229-2233.2002; PMID: 12069978
   PubMed Web of Science ®Google Scholar
• Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood?. Trends Microbiol 2002; 10:370 - 5; http://dx.doi.org/10.1016/S0966-842X(02)02405-8; PMID: 12160635
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Broutet N, Cantagrel A, Andersen LP, Alarcon T, López-Brea M, Mégraud F. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori.. Eur J Clin Microbiol Infect Dis 2002; 21:549 - 52; http://dx.doi.org/10.1007/s10096-002-0757-6; PMID: 12172749
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al, European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646 - 64; http://dx.doi.org/10.1136/gutjnl-2012-302084; PMID: 22491499
   PubMed Web of Science ®Google Scholar
• Novo Y, Gavinet AM, Megraud F, Bebear C. Susceptibility of Campylobacter pylori to nitroimidazole compounds in vitro. P 165-7 In: Megraud F, Lamouliatte H (Eds) Gastroduodenal pathology and Campylobacter pylori. Excerpta Medica ICS847, 1989. Amsterdam.
   Google Scholar
• Mattila J, Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983; 23:721 - 5; http://dx.doi.org/10.1128/AAC.23.5.721; PMID: 6870221
   PubMed Web of Science ®Google Scholar
• Adamsson I, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999; 44:629 - 40; http://dx.doi.org/10.1093/jac/44.5.629; PMID: 10552979
   PubMed Web of Science ®Google Scholar
• Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori.. Ann Intern Med 2003; 139:483 - 7; http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00011; PMID: 13679325
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34 - 42; http://dx.doi.org/10.1136/gutjnl-2012-302254; PMID: 22580412
   PubMed Web of Science ®Google Scholar
• Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, Andersson DI. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.. Proc Natl Acad Sci U S A 2001; 98:14607 - 12; http://dx.doi.org/10.1073/pnas.241517298; PMID: 11717398
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.. Eur J Clin Microbiol Infect Dis 2001; 20:820 - 3; http://dx.doi.org/10.1007/s100960100611; PMID: 11783701
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45:4006 - 10; http://dx.doi.org/10.1128/JCM.00740-07; PMID: 17942652
   PubMed Web of Science ®Google Scholar
• Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17:719 - 26; http://dx.doi.org/10.1046/j.1365-2036.2003.01461.x; PMID: 12641522
   PubMed Web of Science ®Google Scholar
• Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori.. Antimicrob Agents Chemother 2001; 45:727 - 33; http://dx.doi.org/10.1128/AAC.45.3.727-733.2001; PMID: 11181351
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772 - 81; http://dx.doi.org/10.1136/gut.2006.101634; PMID: 17170018
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808 - 25; http://dx.doi.org/10.1111/j.1572-0241.2007.01393.x; PMID: 17608775
   PubMed Web of Science ®Google Scholar
• Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, Itoi T, Sakai Y, Moriyasu F, Osaka Y, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23:Suppl 2 S171 - 4; http://dx.doi.org/10.1111/j.1440-1746.2008.05408.x; PMID: 19120893
   PubMedGoogle Scholar
• Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, et al, Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68:450 - 6; http://dx.doi.org/10.1093/jac/dks407; PMID: 23099849
   PubMed Web of Science ®Google Scholar
• Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11:507 - 10; http://dx.doi.org/10.1016/j.cgh.2012.12.007; PMID: 23267869
   PubMed Web of Science ®Google Scholar
• Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, Mégraud F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori.. J Clin Microbiol 2003; 41:397 - 402; http://dx.doi.org/10.1128/JCM.41.1.397-402.2003; PMID: 12517879
   PubMed Web of Science ®Google Scholar
• Rüssmann H, Adler K, Haas R, Gebert B, Koletzko S, Heesemann J. Rapid and accurate determination of genotypic clarithromycin resistance in cultured Helicobacter pylori by fluorescent in situ hybridization. J Clin Microbiol 2001; 39:4142 - 4; http://dx.doi.org/10.1128/JCM.39.11.4142-4144.2001; PMID: 11682543
   PubMed Web of Science ®Google Scholar
• Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori.. J Clin Microbiol 2009; 47:3600 - 7; http://dx.doi.org/10.1128/JCM.00744-09; PMID: 19759218
   PubMed Web of Science ®Google Scholar
• Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavanc R, Gallaz L, et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause?. Gastroenterol Clin Biol 2002; 26:216 - 9; PMID: 11981460
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15:87 - 103; http://dx.doi.org/10.1046/j.1365-2036.2001.00876.x; PMID: 11136282
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70:484 - 92; http://dx.doi.org/10.1067/mcp.2001.119721; PMID: 11719736
   PubMed Web of Science ®Google Scholar
• Demir K, Ormeci A, Emrence Z, Gokturk S, Baran B, Mutlauay Soyer O, et al. Effect of genotypic differences in CYP2C19 and on cure rates for Helicobacter pylori infection by triple therapy with different proton pump inhibitors. DDW 2013; 2013:a1915
   Google Scholar
• Perri F, Clemente R, Festa V, Quitadamo M, Conoscitore P, Niro G, Ghoos Y, Rutgeerts P, Andriulli A. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998; 30:146 - 50; PMID: 9675647
   PubMed Web of Science ®Google Scholar
• Broutet N, Marais A, Lamouliatte H, de Mascarel A, Samoyeau R, Salamon R, Mégraud F. cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 2001; 39:1319 - 22; http://dx.doi.org/10.1128/JCM.39.4.1319-1322.2001; PMID: 11283049
   PubMed Web of Science ®Google Scholar
• Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17:99 - 109; http://dx.doi.org/10.1046/j.1365-2036.2003.01396.x; PMID: 12492738
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905 - 13; http://dx.doi.org/10.1016/S0140-6736(11)60020-2; PMID: 21345487
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44:313 - 25; PMID: 20054285
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17:269 - 76; http://dx.doi.org/10.1111/j.1523-5378.2012.00947.x; PMID: 22759326
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.. Clin Exp Gastroenterol 2012; 5:23 - 34; http://dx.doi.org/10.2147/CEG.S25419; PMID: 22457599
   PubMedGoogle Scholar
• Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18:129 - 34; http://dx.doi.org/10.1111/hel.12017; PMID: 23121338
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507 - 14; http://dx.doi.org/10.1016/S0140-6736(11)60825-8; PMID: 21777974
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, et al, H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association). Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013; 47:130 - 5; http://dx.doi.org/10.1097/MCG.0b013e318254ebdd; PMID: 22647827
   PubMed Web of Science ®Google Scholar
• Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, et al. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.. Helicobacter 2012; 17:216 - 23; http://dx.doi.org/10.1111/j.1523-5378.2012.00937.x; PMID: 22515360
   PubMed Web of Science ®Google Scholar
• Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, Di Renzo L, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18:5669 - 78; http://dx.doi.org/10.3748/wjg.v18.i40.5669; PMID: 23155306
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter 2011; 16:131 - 8; http://dx.doi.org/10.1111/j.1523-5378.2011.00826.x; PMID: 21435091
   PubMed Web of Science ®Google Scholar
• Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother 2009; 53:3097 - 9; http://dx.doi.org/10.1128/AAC.01552-08; PMID: 19380599
   PubMed Web of Science ®Google Scholar
• Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, et al, For the Japan GAST Study Group.. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. [Epub ahead of print] J Gastroenterol 2013; http://dx.doi.org/10.1007/s00535-012-0731-8; PMID: 23307042
   PubMed Web of Science ®Google Scholar
• Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, Yang HB, Cheng HC, Sheu BS. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. Helicobacter 2012; 17:210 - 5; http://dx.doi.org/10.1111/j.1523-5378.2012.00935.x; PMID: 22515359
   PubMed Web of Science ®Google Scholar
• Asaoka D, Nagahara A, Matsuhisa T, Takahashi SI, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T, et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: A multicenter study in the Tokyo metropolitan area. Helicobacter 2013; PMID: 23773231
   PubMed Web of Science ®Google Scholar
• Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, et al. Effects of different dosing schedules of amoxicillin on the eradication rates of Helicobacter pylori by triple therapy with a proton pump inhibitor, amoxicillin, and either clarithromycin or metronidazole. DDW 2013; 2013:a245
   Google Scholar
• Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35:941 - 7; http://dx.doi.org/10.1111/j.1365-2036.2012.05053.x; PMID: 22372560
   PubMed Web of Science ®Google Scholar
• D’Elios MM, Silvestri E, Emmi G, Barnini T, Prisco D. Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen. Expert Rev Gastroenterol Hepatol 2012; 6:437 - 9; http://dx.doi.org/10.1586/egh.12.32; PMID: 22928895
   PubMed Web of Science ®Google Scholar
• Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.. Hepatogastroenterology 2010; 57:1314 - 9; PMID: 21410079
   PubMed Web of Science ®Google Scholar
• Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25:155 - 68; http://dx.doi.org/10.1111/j.1365-2036.2006.03179.x; PMID: 17229240
   PubMed Web of Science ®Google Scholar
• Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069 - 79; http://dx.doi.org/10.1111/j.1365-2036.2010.04457.x; PMID: 21039671
   PubMed Web of Science ®Google Scholar
• Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L, Manca A, Are BM, Massarelli G, Mura I, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4:106 - 12; http://dx.doi.org/10.1046/j.1523-5378.1999.99002.x; PMID: 10382124
   PubMed Web of Science ®Google Scholar
• Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y, et al, H pylori Working Groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53:230 - 43; PMID: 21558964
   PubMed Web of Science ®Google Scholar
• Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, Leonetti F, Severi C. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18:1450 - 4; http://dx.doi.org/10.1007/s11695-008-9477-z; PMID: 18443890
   PubMed Web of Science ®Google Scholar